PT - JOURNAL ARTICLE AU - Wang, Ji AU - Deng, Caiguangxi AU - Liu, Ming AU - Liu, Yihao AU - Li, Liubing AU - Huang, Zhangping AU - Shang, Liru AU - Jiang, Juan AU - Li, Yongyong AU - Mo, Ruohui AU - Zhang, Hui AU - Liu, Min AU - Peng, Sui AU - Xiao, Haipeng TI - Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the Receptor Binding Domain AID - 10.1101/2022.02.19.22271215 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.19.22271215 4099 - http://medrxiv.org/content/early/2022/02/21/2022.02.19.22271215.short 4100 - http://medrxiv.org/content/early/2022/02/21/2022.02.19.22271215.full AB - A recent MMWR reported that the effectiveness of a 3rd dose of SARS-CoV-2 mRNA vaccine waned quickly in the Omicron-predominant period. Similarly, a substantial decline of immune responses induced by a 3rd dose of inactivated vaccines was also observed in our study. In response to the fast waning immune response and the great threat of Omicron variant of concern (VOC) to frontline healthcare workers (HCWs), 38 HCWs who were in our previous cohort investigating responses to the first three doses of inactivated vaccines participated in the current study and volunteered to receive a 4th homologous booster. Here, we demonstrated that the 4th dose is safe and capable of recalling waned immune responses 6 months after the 3rd dose. However, a greater suppression on the induction of overall Neutralizing antibodies (NAbs) and NAbs targeting the receptor-binding domain (RBD) was found in participants with stronger immune responses after the 3rd dose. As a result, a stepwise elevation of RBD-NAbs from the 1st to the 3rd vaccination achieved a “turning point”. The peak RBD-NAbs level induced by the 4th dose was inferior to the peak of the 3rd dose. Accompanied with reduced induction of RBD-NAbs, the immune system shifted responses to the nucleocapsid protein (NP) and the N-terminal domain (NTD) of the spike protein. Although NTD directed antibodies are capable of neutralization, they only compensated the loss of RBD-NAbs to ancestral SARS-CoV-2 virus but not to the Omicron variant due to a substantial conformational change of Omicron NTD. This longitudinal clinical study monitored the immune response of the same cohort for every doses, shaping a relationship between the trajectory of immune focus and the dynamics of the neutralizing potency against the evolving virus. Our data reveal that immune responses could not be endlessly elevated, while suppression of heightened immune responses focusing on one subunit together with a shift of immune responses to other subunits would occur after repeated vaccination. Thus, an updated vaccine with more diverse epitopes capable of inducing NAbs against VOCs would be a future direction for boosters.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2200055564Funding StatementThe work is supported by The Talent Program of the First Affiliated Hospital, Sun Yat-sen University (Y70311), The Hundred Talent Program of Sun Yat-sen University (Y61224), and the Science and Technology Program of Guangzhou (202103000076).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of FAH-SYSU gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors will share de-identified individual participant data on request with researchers who provide a methodologically proposal and can conduct analyses that achieve the aims of the proposal. Reasonable requests for data sharing can be directed to xiaohp@mail.sysu.edu.cn by email. To gain access data requestors will need to sign a data access agreement.